HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/13/2018)... ... ... Illumina, Kaiser Permanente, ResMed and Aetna were just a few of the ... events company has hosted an impressive guest list of Fortune 500 businesses, namely due ... who visits receives a completely customized experience, right down to the menu and the ...
(Date:12/13/2018)... , ... December 13, 2018 , ... ... released a must-see documentary entitled “What Researchers Need to Know about Antibody ... in Life Science Research series. The goal of this film is to educate ...
(Date:12/10/2018)... ... December 10, 2018 , ... Today, RoosterBio ... their shared goal of accelerating the development of the Regenerative Medicine field. ... TRT’s core technology around human umbilical cord perivascular cells (HUCPVCs). Together, it ...
Breaking Biology News(10 mins):
(Date:12/13/2018)... ... December 12, 2018 , ... Helping conclude Healthy Aging Month this past September, ... aid within its Vision and Hearing campaign that sets out to shed light on ... despite continued efforts to destigmatize hearing aids over the years, 9 out of 10 ...
(Date:12/10/2018)... SAN DIEGO (PRWEB) , ... ... ... Ltd., a fully integrated Contract Development and Manufacturing Organization (CDMO) with sites ... characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions for monoclonal ...
(Date:12/5/2018)... (PRWEB) , ... December 05, 2018 , ... The incredible ... paid tribute to in the European Parliament by Carlos Moedas, the European Commissioner for ... EU Research and Innovation in Our Daily Lives, Commissioner Moedas spoke at length of ...
(Date:12/5/2018)... CHARLOTTESVILLE, Va. and LONDON (PRWEB) , ... ... ... Atlantic Research Group (ARG), an established North American full-service contract research organization ... CRO. Effective immediately, the transaction significantly strengthens ARG’s reach and experience in ...
Breaking Biology Technology:
Cached News: